Global Cancer Biomarkers Market – Industry Trends and Forecast to 2030

Cancer Biomarkers Market Analysis and Size

As per the Globocan 2020 statistics, there were around 467,965 new cancer cases in France, with 185,621 deaths. As per the Foundation de France, cancer affects more than 350,000 people yearly and kills close to 150,000, resulting in approximately one-third of all deaths. Cancer biomarkers are increasingly gaining much importance in emerging economies, coupled with increasing awareness about them in remote areas. Thus, cancer biomarkers have been discovered to play a critical role in risk assessment and early diagnosis.

Data Bridge Market Research analyses that the cancer biomarkers market, which was USD 13.24 billion in 2022, would rocket up to USD 36.74 billion by 2030 and is expected to undergo a CAGR of 13.6% during the forecast period from 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Cancer Biomarkers Market Scope and Segmentation

Market Definition

Cancer biomarkers are used to detect how the body responds to a treatment of any type of condition or disease and help investigate organ functions and other health conditions. These play a major role in imaging technology, offering clear imaging of oncology tumors and other problems. Numerous molecules, proteins, or hormones, such as DNA (genes), can be biomarkers.

Global Cancer Biomarkers Market Dynamics

Drivers

• Increasing R&D activities Associated with Cancer Biomarkers

The rising development of research related to cancer biomarkers is helping boost the market's growth. For instance, in 2019, Hitachi and the Centre Léon Bérard cancer center in France promoted R&D to improve the efficiency of cancer diagnosis and treatment by creating the Hitachi Lyon Lab. The research also involves the identification of biomarkers in the context of resistance with the utilization of genomic data, which may enable the prediction of responses and prognoses post-radiation treatment. Thus, as a result, the high cancer burden and increased R&D activities drive market growth.

• Rise in Product Developments Associated with Biomarkers

There have been strategic developments by major market players which are helping to boost the market's growth over the forecast period. For instance, Vela Diagnostics launched new next-generation sequencing (NGS)-based panels to identify RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens in 2022. The panels are primarily focused (60 genes) and comprehensive (525 genes). Furthermore, in 2022, researchers at Clarkson University in New York launched a set of protein biomarkers that could be widely used to screen for breast cancer in breast milk or blood serum. The biomarkers were discovered for a type of cancer named invasive ductal carcinoma (IDC). Thus, these type of product launches is helping in boosting the growth of the market.

Opportunities

• Increasing Cancer Cases

As per the Globocan 2020 data, there were around 457,960 new cancer cases in the U.K., with breast, lung, colon, prostate, and skin cancer being the most prevalent types of cancer detected. As per the same source, Italy witnessed 415,269 new cancer cases and around 174,759 deaths. As a result of the increasing number of cancer cases, cancer biomarkers are widely used in research institutes and hospitals, which is further expected to grow significantly during the forecast period.

• Growing Partnerships Between Market Players

There have been growing partnerships between different organizations that lead to market growth. For instance, Medable partnered with Aural Analytics to assess remote data capture and digital biomarkers in cancer patients as part of its cancer moonshot work in 2021. This partnership involves tracking speech and language-based information associated with motor, cognitive and respiratory functions and analyzing objective outcomes data to surge the measurement of patients through digital biomarkers. Thus, this factor boosts market growth.

Restraints/Challenges

• High treatment costs

The difficulties, such as high investment requirements, increased treatment costs, and expensive capital expenditure on multiple diagnostic equipments, are anticipated to limit market expansion. The equipment is not always affordable in underdeveloped countries. Thus, this factor restricts the market growth.

This cancer biomarkers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cancer biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2022, Abbott Laboratories launched Lingo, a consumer bio wearable that can track important body signals and assist consumers in better understanding and improving their overall health. It could enable biohackers to use a continuous data stream compared to periodic finger-prick tests, urine samples, and breath readings.

• In 2022, OncoDNA, a genomic and prognostic business, launched the OncoDEEP kit. The kit offers a complete workflow solution that enables laboratories with NGS capabilities to undertake thorough biomarker testing, perform advanced data analysis, and assist oncologists in providing the most effective and customized cancer treatments for their patients.

Global Cancer Biomarkers Market Scope

The cancer biomarkers market is segmented on the basis of product, technology, service, type, application, and indication. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Consumables
• Services
• Software
• Growth Hormone Therapy

Technology

• OMICS
• Imaging Technology
• Immunoassays
• Cytogenetics
• Bioinformatics

Service

• Sample Preparation
• Assay Development
• Biomarkers
• Testing

Type

• Safety
• Efficacy
• Predictive
• Surrogate
• Prognostic
• Pharmacodynamics
• Validation
• Protein
• Genetic

Application 

• Diagnostics
• Drug Discovery and Development
• Personalized Medicine
• Disease Risk Assessment
• Others

Indication

• Cancer
• Solid biopsy
• Liquid Biopsy                                               
• Infectious Diseases
• Immune Disorders
• Neurological Disorders
• Cardiovascular Disorders
• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Cervical Cancer
• Other Disease Indications

Cancer Biomarkers Market Regional Analysis/Insights

The cancer biomarkers market is analyzed and market size insights and trends are provided by product, technology, service, type, application, and indication as referenced above.

The countries covered in the cancer biomarkers market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cancer biomarkers market due to the strong base of healthcare facilities, increasing investment from major market players in the growth of advanced devices, and an increasing number of processes relating to drug development. Also, the detection of some tumors, monitoring of biological response to cancer therapy, and an increasing number of research activities in this region boost the market growth

Asia-Pacific is expected to witness significant growth due to the rise in government initiatives to promote awareness, increased medical tourism, rising research activities in the region, a growing prevalence of cancer, and the increased demand for quality healthcare.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The cancer biomarkers market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cancer biomarkers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cancer biomarkers market. The data is available for historic period 2011-2021.

Competitive Landscape and Cancer Biomarkers Market Share Analysis

The cancer biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer biomarkers market.

Some of the major players operating in the cancer biomarkers market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• QIAGEN (Germany)
• PerkinElmer, Inc. (U.S.)
• Merck KGaA (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• Enzo Biochem, Inc. (U.S.)
• Charles River Laboratories (U.S.)
• Eurofins Scientific (Luxembourg)
• Agilent Technologies, Inc. (U.S.)
• Bruker (U.S.)
• Siemens (U.S.)
• Epigenomics AG (Germany)
• General Electric (U.S.)

SKU-1710